XERS - Xeris Pharmaceuticals GAAP EPS of -$0.42 misses by $0.14 net product revenue of $21.36M

Xeris Pharmaceuticals press release (NASDAQ:XERS): Q4 GAAP EPS of -$0.42 misses by $0.14. Net Product Revenue of $21.36M (+201.3% Y/Y). Cash, cash equivalents, and short-term investments at December 31, 2021, was $102.4 million compared to $133.8 million at December 31, 2020. Outlook: Net product revenue of $105 million to $120 million for full-year 2022. Year-end 2022 cash, cash equivalents, and short-term investments in the range of $90 million to $110 million

For further details see:

Xeris Pharmaceuticals GAAP EPS of -$0.42 misses by $0.14, net product revenue of $21.36M